Related references
Note: Only part of the references are listed.Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom
Han Geul Byun et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2021)
First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis
Siddharth Singh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
The Cost of Inflammatory Bowel Disease Management Matches with Clinical Course: A Single Outpatient Centre Analysis
Mariabeatrice Principi et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2020)
Micronutrient Absorption and Related Outcomes in People with Inflammatory Bowel Disease: A Review
Kyle Kilby et al.
NUTRIENTS (2019)
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults
Christopher Andrew Lamb et al.
GUT (2019)
Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease
S. Singh et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
The current state of the art for biological therapies and new small molecules in inflammatory bowel disease
Sudarshan Paramsothy et al.
MUCOSAL IMMUNOLOGY (2018)
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management
Fernando Gomollon et al.
JOURNAL OF CROHNS & COLITIS (2017)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Marcus Harbord et al.
JOURNAL OF CROHNS & COLITIS (2017)
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
Siew C. Ng et al.
LANCET (2017)
Costs of providing infusion therapy for patients with inflammatory bowel disease in a hospital-based infusion center setting
Anita Afzali et al.
JOURNAL OF MEDICAL ECONOMICS (2017)
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model
Rachel Archer et al.
HEALTH TECHNOLOGY ASSESSMENT (2016)
Accelerated Infliximab Infusion: Safety, Factors Predicting Adverse Events, Patients' Satisfaction and Cost Analysis. A Cohort Study in IBD Patients
S. Mazzuoli et al.
PLOS ONE (2016)
Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments
Bruno Rafael Ramos de Mattos et al.
MEDIATORS OF INFLAMMATION (2015)
Epidemiology and risk factors for IBD
Ashwin N. Ananthakrishnan
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review
Kelly L. Stoner et al.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2015)
Budget Impact Analysis Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force
Sean D. Sullivan et al.
VALUE IN HEALTH (2014)
Evaluating the administration costs of biologic drugs: development of a cost algorithm
Ebenezer K. Tetteh et al.
HEALTH ECONOMICS REVIEW (2014)
The burden of inflammatory bowel disease in Europe
Johan Burisch et al.
JOURNAL OF CROHNS & COLITIS (2013)
Administration costs of intravenous biologic drugs for rheumatoid arthritis
Erkki J. Soini et al.
SPRINGERPLUS (2013)
Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review
Natalie A. Molodecky et al.
GASTROENTEROLOGY (2012)
Epidemiology and Natural History of Inflammatory Bowel Diseases
Jacques Cosnes et al.
GASTROENTEROLOGY (2011)
MECHANISMS OF DISEASE Inflammatory Bowel Disease
Clara Abraham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Review: Ulcerative colitis: current treatment strategies and future prospects
Sagar Garud et al.
Therapeutic Advances in Gastroenterology (2009)
Share Paper
